Cathleen Park
Hematology & Oncology · Orange, CANPI 1700319043
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Immunitybio, Inc. at 38.6% of the total. 2025 is the largest year on record at $6,114, more than ten times the $125 reported in 2021.
Across 25 payments — averaging $259.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Immunitybio, Inc.$3K
- Janssen Research & Development, LLC$2K
- Johnson & Johnson$1K
- Pfizer$277
- Daiichi Sankyo Inc.$238
- Janssen Scientific Affairs, LLC$227
- plus $456 from 4 others
Across 16 payments — averaging $19,455 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$175K
- Mirati Therapeutics, Inc.$96K
- Pfizer$40K
What the payments were for
- Consulting fees$2,40037%
- Speaking & faculty fees$2,50039%
- Food & beverage$1,56924%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Immunitybio, Inc. | 1 | $2,500 |
| Janssen Research & Development, LLC | 3 | $1,540 |
| Johnson & Johnson | 3 | $1,243 |
| Pfizer | 5 | $277 |
| Daiichi Sankyo Inc. | 4 | $238 |
| Janssen Scientific Affairs, LLC | 4 | $227 |
| AstraZeneca | 2 | $186 |
| Bristol Myers Squibb | 1 | $125 |
| Beigene USA, Inc. | 1 | $122 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,481 in reported general payments places this provider in the 60th percentile of 1,363 hematology & oncology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 11 | $164,319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $186 | $164,31911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Orange
- Catherine CoombsOrange$786K
- Arash Rezazadeh KalebastyOrange$516K
- Misako NagasakaOrange$507K
- Elizabeth BremOrange$335K
- May ChoOrange$334K
- Angela FleischmanOrange$255K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.